id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S10170 R37124 |
Blotière (Levetiracetam) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Hypospadias | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
0.34 [0.02;6.04] C excluded (control group) |
0/579 7/2,997 | 7 | 579 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10037 R36209 |
Blotière (Levetiracetam) (Controls unexposed NOS) (Mixed indications), 2019 | Hypospadias | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 0.48 [0.03;7.69] C | 0/579 3,371/1,875,733 | 3,371 | 579 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9010 R30649 |
Tomson (Levetiracetam), 2018 | Hypospadias | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.70 [0.08;5.82] C | 1/599 6/2,514 | 7 | 599 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8991 R30539 |
Hernández-Díaz (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2012 | Hypospadias | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No Controls: mixed indications | 3.47 [0.07;175.33] C | 0/450 0/1,562 | 0 | 450 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9002 R30579 |
Morrow (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2006 | Hypospadias/genitourinary tract defects | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 2.29 [0.13;42.00] C | 0/22 6/647 | 6 | 22 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 1.01 [0.26;3.95] | 3,384 | 1,650 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Levetiracetam) (Controls unexposed NOS) (Mixed indications; 2: Levetiracetam; 3: Levetiracetam) (Controls exposed to Lamotrigine, sick; 4: Levetiracetam) (Controls exposed to Lamotrigine, sick;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 10170